Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar-Apr;33(2):109-111.
doi: 10.1097/CRD.0000000000000589. Epub 2025 Feb 3.

Cardiotoxicity of Breast Cancer Chemotherapy

Sacha A Roberts  1 , William H Frishman  1
Affiliations
Review

Cardiotoxicity of Breast Cancer Chemotherapy

Sacha A Roberts et al. Cardiol Rev. 2025 Mar-Apr.

Abstract

Breast cancer is one of the leading causes of malignancy affecting women in the United States. Although many effective treatments are available, most come with notable side effects that providers and patients must take into consideration. Various classes of chemotherapeutic agents, including anthracyclines and human epidermal growth factor receptor-2 antagonists, are known to be toxic to myocardial tissue. In this review article, we discuss what is reported in the literature regarding the cardiotoxicity of these agents as well as how to monitor and prevent cardiac injury and dysfunction.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors have no conflicts of interest to report.

References

    1. Shah AN, Gradishar WJ. “Adjuvant anthracyclines in breast cancer: what is their role?” Oncologist. 2018;23:1153–1161.
    1. Bhagat A, Kleinerman ES. “Anthracycline-induced cardiotoxicity: causes, mechanisms, and prevention.” Adv Exp Med Biol. 2020;1257:181–192.
    1. Zhang S, Liu X, Bawa-Khalfe T, et al. “Identification of the molecular basis of doxorubicin-induced cardiotoxicity.” Nat Med. 2012;18:1639–1642.
    1. Alexander J, Dainiak N, Berger HJ, et al. “Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.” Engl J Med. 2010;300:278–283.
    1. Choi BW, Berger HJ, Schwartz PE, et al. “Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance.” Am Heart J. 1983;106:638–643.

MeSH terms